The estimated Net Worth of Capital Viii, Llc Vivo Capi... is at least 19 百万$ dollars as of 9 March 2020. Capital Capi owns over 528 units of Crinetics Pharmaceuticals Inc stock worth over 8,532,692$ and over the last 6 years Capital sold CRNX stock worth over 10,481,102$.
Capital has made over 5 trades of the Crinetics Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital sold 528 units of CRNX stock worth 10,296$ on 9 March 2020.
The largest trade Capital's ever made was selling 417,000 units of Crinetics Pharmaceuticals Inc stock on 20 March 2019 worth over 9,278,250$. On average, Capital trades about 94,274 units every 71 days since 2019. As of 9 March 2020 Capital still owns at least 168,165 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Capital Capi stock trades at the bottom of the page.
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over 52,514,606$ worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth 62,800,483$ . The most active insiders traders include Advisors Llcperceptive Life...、Jack Nielsen、Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of 3,116,248$. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth 159,570$.
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include: